Logo image of OGI

ORGANIGRAM GLOBAL INC (OGI) Stock Fundamental Analysis

NASDAQ:OGI - Nasdaq - CA68617J1003 - Common Stock - Currency: USD

1.43  -0.13 (-8.33%)

After market: 1.4399 +0.01 (+0.69%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OGI. OGI was compared to 193 industry peers in the Pharmaceuticals industry. OGI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OGI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

OGI had negative earnings in the past year.
OGI had a negative operating cash flow in the past year.
In the past 5 years OGI always reported negative net income.
OGI had negative operating cash flow in 4 of the past 5 years.
OGI Yearly Net Income VS EBIT VS OCF VS FCFOGI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

OGI has a better Return On Assets (3.14%) than 86.01% of its industry peers.
Looking at the Return On Equity, with a value of 4.32%, OGI belongs to the top of the industry, outperforming 84.97% of the companies in the same industry.
Industry RankSector Rank
ROA 3.14%
ROE 4.32%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
OGI Yearly ROA, ROE, ROICOGI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

With an excellent Profit Margin value of 8.70%, OGI belongs to the best of the industry, outperforming 86.01% of the companies in the same industry.
OGI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 8.7%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGI Yearly Profit, Operating, Gross MarginsOGI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OGI has more shares outstanding
OGI has more shares outstanding than it did 5 years ago.
OGI has a worse debt/assets ratio than last year.
OGI Yearly Shares OutstandingOGI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OGI Yearly Total Debt VS Total AssetsOGI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.13, we must say that OGI is in the distress zone and has some risk of bankruptcy.
OGI has a Altman-Z score (-0.13) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.11 indicates that OGI is not too dependend on debt financing.
OGI has a Debt to Equity ratio (0.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC9.03%
OGI Yearly LT Debt VS Equity VS FCFOGI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.42 indicates that OGI has no problem at all paying its short term obligations.
With a Current ratio value of 3.42, OGI perfoms like the industry average, outperforming 59.59% of the companies in the same industry.
OGI has a Quick Ratio of 1.90. This is a normal value and indicates that OGI is financially healthy and should not expect problems in meeting its short term obligations.
OGI's Quick ratio of 1.90 is in line compared to the rest of the industry. OGI outperforms 43.01% of its industry peers.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 1.9
OGI Yearly Current Assets VS Current LiabilitesOGI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

OGI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.08%.
Looking at the last year, OGI shows a quite strong growth in Revenue. The Revenue has grown by 10.84% in the last year.
The Revenue has been growing by 67.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.78%
Revenue 1Y (TTM)10.84%
Revenue growth 3Y23.02%
Revenue growth 5Y67.11%
Sales Q2Q%71.46%

3.2 Future

Based on estimates for the next years, OGI will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.85% on average per year.
OGI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.93% yearly.
EPS Next Y48.8%
EPS Next 2Y31.91%
EPS Next 3Y25.11%
EPS Next 5Y16.85%
Revenue Next Year3.82%
Revenue Next 2Y26.13%
Revenue Next 3Y22.1%
Revenue Next 5Y17.93%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OGI Yearly Revenue VS EstimatesOGI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
OGI Yearly EPS VS EstimatesOGI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OGI is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGI Price Earnings VS Forward Price EarningsOGI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGI Per share dataOGI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as OGI's earnings are expected to grow with 25.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.91%
EPS Next 3Y25.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OGI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANIGRAM GLOBAL INC

NASDAQ:OGI (8/15/2025, 6:12:19 PM)

After market: 1.4399 +0.01 (+0.69%)

1.43

-0.13 (-8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)12-16 2025-12-16/amc
Inst Owners5.59%
Inst Owner Change5.05%
Ins Owners2.47%
Ins Owner ChangeN/A
Market Cap191.45M
Analysts77.5
Price Target2.04 (42.66%)
Short Float %6.19%
Short Ratio9.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)258.42%
Min EPS beat(2)-400%
Max EPS beat(2)916.83%
EPS beat(4)2
Avg EPS beat(4)131.47%
Min EPS beat(4)-400%
Max EPS beat(4)916.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-12.23%
Max Revenue beat(2)6%
Revenue beat(4)3
Avg Revenue beat(4)0.09%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)6%
Revenue beat(8)4
Avg Revenue beat(8)-1.86%
Revenue beat(12)6
Avg Revenue beat(12)-0.65%
Revenue beat(16)9
Avg Revenue beat(16)1.46%
PT rev (1m)-1.12%
PT rev (3m)-1.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)51.61%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.19%
Revenue NY rev (1m)3.38%
Revenue NY rev (3m)3.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.36
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS1.05
BVpS2.12
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.14%
ROE 4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 8.7%
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.7%
Cap/Sales 5.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 1.9
Altman-Z -0.13
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)118.74%
Cap/Depr(5y)166.77%
Cap/Sales(3y)18.54%
Cap/Sales(5y)32.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.78%
EPS Next Y48.8%
EPS Next 2Y31.91%
EPS Next 3Y25.11%
EPS Next 5Y16.85%
Revenue 1Y (TTM)10.84%
Revenue growth 3Y23.02%
Revenue growth 5Y67.11%
Sales Q2Q%71.46%
Revenue Next Year3.82%
Revenue Next 2Y26.13%
Revenue Next 3Y22.1%
Revenue Next 5Y17.93%
EBIT growth 1Y8.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.97%
EBIT Next 3Y49.25%
EBIT Next 5Y29.71%
FCF growth 1Y-7.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.66%
OCF growth 3YN/A
OCF growth 5YN/A